Latex Agglutination Test Kits Market Size, Share & Trends Analysis Report By Product Type (ELISA, Indirect Fluorescent), By Test Type (Antibody Detection), By Sample Type (Blood), By End-use, By Region, And Segment Forecasts, 2024 - 2030

Latex Agglutination Test Kits Market Trends

The global latex agglutination test kits market size was estimated at USD 639.02 million in 2023 and is anticipated to grow at a compound annual growth rate (CAGR) of 5.65% from 2024 to 2030. The diverse application areas of latex agglutination test kits, growing incidence of autoimmune & infectious diseases, and increasing adoption of point-of-care diagnostics are the key factors anticipated to drive the latex agglutination test kits market over the forecast period. Moreover, factors such as increasing training programs on various laboratory test including latex agglutination test is expected to boost the market expansion.

For instance, the Autonomous University of Barcelona (UAB) in Spain is conducting a workshop on various laboratory tests including latex agglutination for detection, enumeration, isolation, identification of microorganisms.

The global incidence of meningitis has been on the rise, as reported by the World Health Organization (WHO) between November 2022 and January 2023. During this period, there were 559 cases of meningitis, including 111 laboratory-confirmed cases and 18 deaths, compared to 231 cases reported in the same period the previous year. The escalating prevalence of diseases has led to a greater demand for latex agglutination test kits as they offer a convenient and affordable solution.

In addition, robust research and development initiatives aimed at evaluating and improving these products and the growing awareness of infectious diseases present significant market growth opportunities in the forecast period. For instance, as of June 2023, the Global Fund had invested around USD 17.9 billion in malaria control programs. These factors are anticipated to positively impact the market growth.

Public awareness campaigns that focus on recognizing the symptoms of infectious diseases and implementing preventive measures are crucial in the management of disease epidemics. The CDC is continuously striving to control disease epidemics in India, as it is one of the high-risk countries. With initial focus on preventing HIV/AIDS, the CDC has now expanded its scope to address additional diseases in India, including influenza & tuberculosis; immunization; and antimicrobial resistance. This initiative facilitated the strengthening of surveillance and laboratory capacity in the country to respond to disease outbreaks. Thus, increased patient awareness has led to high demand for latex agglutination test kits across the globe.

Market Concentration & Characteristics

The global latex agglutination test kits market is market by moderate level of innovation owing to the increased demand for quick and accurate diagnosis of the autoimmune disease and other infections. Companies are involved in the research and development activities to enhance the specificity and sensitivity if the test kits as well as to expand their operations.

The level of merger and acquisition activities in the market is low as the market is competitive and fragmented with various local players operating in different regions. The market has witnesses only a few merger and acquisitions in the recent years, as the companies emphasizes on organic development approaches.

Furthermore, the market is subject to high level of regulatory impact as the products within this market is used in the medical diagnosis and testing. The companies operating in the market are obligated to adhere to the regulatory requirements of various governmental authorities.

In addition, the end-user concentration in the market is high as it is concentrated amongst a few end-users, primarily hospital-based laboratories and clinical laboratories. These end-users require quick and authentic diagnosis of various conditions and diseases and account for the majority of the market share.

Product Type Insights

The ELISA segment held the largest market share of 44.32% in 2023 and is projected to maintain its dominance over the forecast period. The trend towards point-of-care testing and rapid diagnostics has spurred the adoption of ELISA latex agglutination kits in clinics and smaller healthcare facilities. In addition, technological advancements, including automation, miniaturization, and digital platforms, enhance the efficiency and accuracy of ELISA testing, further driving the segment.

Moreover, the pharmaceutical and biotechnology industries extensively utilize ELISA kits for drug development, clinical trials, and research purposes. Global health crises, like the COVID-19 pandemic, emphasize the importance of diagnostic testing and lead to increased investments and market growth. Additionally, the trend towards personalized medicine necessitates specific diagnostic tools, and ELISA kits can be customized for various applications. These driving factors collectively contribute to the robust growth of the ELISA market.

Test Type Insights

The antibody detection segment held the largest market share of 64.83% in 2023 and is estimated to grow at a fastest CAGR over the forecast period. Antibody detection latex agglutination tests are popular due to their cost-effectiveness, ease of use, and versatility. They play a vital role in diagnosing infectious diseases, facilitating quick patient management, and enabling research and surveillance. For instance, in rheumatoid arthritis rheumatoid factor is calculated by using antibody detection. Thus, rising incidence of rheumatoid arthritis is boosting the segments revenue.

The antigen testing segment is expected to grow at a significant rate during the study period. The growth is attributed to the high specificity and sensitivity of the antigen detection kits by latex agglutination in clinical settings. Antigen detection test kits offer rapid result and does not require a specialist for perming the test. The capabilities are expected to boost the segment growth over the forecast period.

Sample Type Insights

The bloodsegment held the largest market share of 53.15% in 2023 and is projected to maintain its dominance over the forecast period. The blood sample is a preferred choice of sample in antibody and antigen latex agglutination test kits due to the presence of clotting factors in the blood. In addition, diagnosis of various fugal and bacterial infections requires blood samples for the disease identification. These factors are driving the segment growth.

The urine segment is predicted to grow with significant CAGR 5over the forecast period. Owing to the minimal risks associated with the sample collection. Furthermore, the diagnosis of urine sample offers high accuracy, specificity, and sensitivity in the disease diagnosis. These capabilities are anticipated to drive the segment growth over the forecast period.

End-use Insights

The hospital pharmacies segment accounted the highest market share of 53.06% in 2023. The number of medical treatments conducted in hospitals surpasses that of any other healthcare facility, primarily due to favorable reimbursement systems and the prevalence of hospitals as primary care providers in many developing countries. Additionally, the increasing influx of individuals, particularly in rural regions, and the ease of access to hospitals, are expected to further elevate the need for latex agglutination test kits in hospital pharmacies. Consequently, this surge in demand is set to drive growth within this segment.

The retail pharmacy segment held the second largest market share in 2023. This growth can be attributed to various factors, including the enhanced availability of kits for diagnosis of numerous diseases through retail pharmacies. Patients find it increasingly convenient to obtain latex agglutination test kits at their local pharmacies, which has led to a surge in demand for these kits. Moreover, the expanding role of retail pharmacies in offering workshops and guidance on the usage pf latex agglutination has also contributed to the growth of this segment.

Regional Insights

North America accounted for the largest revenue share of 42.97% in 2023 attributed to various factors such as a rise in burden of infectious diseases and presence of major operating players. For instance, according to the U.S. Centers for Disease Control and Prevention (CDC), estimates there have been a substantial number of influenza infection cases in the United States. Between 2010 and 2020, this ranged from approximately 9 million to 41 million cases, resulting in 140 thousand to 710 thousand hospitalizations and 12 thousand to 52 thousand deaths annually in the U.S. Some of the major players operating in the market are Thermo Fischer Scientific Inc., Creative Diagnostics, Bio-Rad Laboratories, Inc., and Cardinal Health. The presence of these leading players in the market is expected to increase the availability of latex agglutination test kits in the region.

Asia Pacific is estimated to grow at the fastest CAGR over the forecast period. The growth of the market can be attributed to several factors, including the presence of well-established healthcare infrastructure in countries like Japan, as well as ongoing advancements in healthcare in India and China. Many countries in the Asia-Pacific (APAC) region are considered developing economies, and they are rapidly adopting innovative diagnostics. Notably, major multinational companies are directing their investments into research and development activities in countries such as India and China, which is a significant driver of the regional market.

Key Companies & Market Share Insights

Some of the key players operating in the market include Thermo Fisher Scientific Inc.; Eurofins Abraxis; and Bioloegend Inc.

• Thermo Fisher Scientific is an American supplier of life sciences solutions, laboratory, specialty diagnostic, pharmaceutical services, analytical instruments and biotechnology services.

• Eurofins Abraxis is a developer, manufacturer and designer of test kits as well as the components for intened, food safety, life sciences and environment.

Creative Diagnostics; Biotium and Atlas Medical GmbH are the other market participants in  the global latex agglutination test kits market.

• Creative Diagnostics is a supplier and manufacturer of viral antigens, critical assay reagents, antibiodies and innovative diagnostic. The company provides manufacturing services and contract biologic reseach and development services including the GMP biologics manufacturing for biopharmaceutical market.

Recent development

• In March 2023, Cardinal Health, collaborated with Bendcare to develop novel health care solutions in rheumatology. Such, initiatives are expected to boost the latex agglutination test kits market during the review period.

• In june 2022,  Thermo Fisher Sceintific collaborated with Diaginostic BioSystem (DBS) to offer a wide spectrum of primary antibodies in U.S. Wit this partnership customers will have the access to company’s high-qiality, innovative and cost-effective products for their day-to-day histopathology staining.

• In April 2022, Bio-Rad Laboratories, Inc. took part in the 32^nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2022. The company demostrated its entire range of infectious disease testing systems, reagents and quality controls for optimizing testing workflows. 

Latex Agglutination Test Kits Market Report Scope

Global Latex Agglutination Test Kits Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented latex agglutination test kits market based on product type, test type, sample type, end-use, and region.

• Product Type Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • ELISA

  • Indirect Fluorescent

  • Hemagglutination Inhibition

  • Serum Neutralization

• Test Type Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Antibody Detection

  • Antigen Testing

• Sample Type Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Blood

  • Urine

  • Cerebrospinal Fluid

  • Others

• End-use Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

• Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait​​​​